Do analysts prefer RFAI or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, RFAI or TXMD?

RF Acquisition Corp II has higher earnings, but lower revenue than TherapeuticsMD. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A TherapeuticsMD $3.02M 7.93 -$570K $0.06 34.50

Do analysts prefer FBIO or TXMD?

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 480.20%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TXMD or ALDX?

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 252.56%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer PYPD or TXMD?

PolyPid presently has a consensus target price of $11.33, suggesting a potential upside of 139.10%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYPD or TXMD more profitable?

PolyPid has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% TherapeuticsMD -6.64% -1.09% -0.78%

TherapeuticsMD (TXMD) Competitors

$2.07 -0.01 (-0.48%)

As of 08/14/2026 04:00 PM Eastern

Compare

TXMD vs. RFAI, FBIO, ALDX, PYPD, and VRCA

Should you buy TherapeuticsMD stock or one of its competitors? TherapeuticsMD's main competitors and comparable companies include RF Acquisition Corp II (RFAI), Fortress Biotech (FBIO), Aldeyra Therapeutics (ALDX), PolyPid (PYPD), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does TherapeuticsMD compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

RF Acquisition Corp II has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. RF Acquisition Corp II's return on equity of 0.00% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
TherapeuticsMD	-6.64%	-1.09%	-0.78%

RF Acquisition Corp II has higher earnings, but lower revenue than TherapeuticsMD.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.7% of TherapeuticsMD shares are owned by institutional investors. 39.1% of RF Acquisition Corp II shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, RF Acquisition Corp II had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for RF Acquisition Corp II and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 2.43 beat RF Acquisition Corp II's score of 1.27 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
RF Acquisition Corp II	Positive
TherapeuticsMD	Very Positive

Summary

RF Acquisition Corp II beats TherapeuticsMD on 6 of the 9 factors compared between the two stocks.

How does TherapeuticsMD compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Fortress Biotech has a net margin of 163.32% compared to TherapeuticsMD's net margin of -6.64%. Fortress Biotech's return on equity of 101.74% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	101.74%	46.34%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Fortress Biotech has higher revenue and earnings than TherapeuticsMD. Fortress Biotech is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.54	$6.82M	$3.17	0.92
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Fortress Biotech presently has a consensus target price of $17.00, indicating a potential upside of 480.20%. Given Fortress Biotech's stronger consensus rating and higher probable upside, equities analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Fortress Biotech had 7 more articles in the media than TherapeuticsMD. MarketBeat recorded 9 mentions for Fortress Biotech and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 2.43 beat Fortress Biotech's score of 0.67 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Positive
TherapeuticsMD	Very Positive

Summary

Fortress Biotech beats TherapeuticsMD on 13 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to Aldeyra Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

TherapeuticsMD has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 252.56%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TherapeuticsMD has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, TherapeuticsMD and TherapeuticsMD both had 2 articles in the media. TherapeuticsMD's average media sentiment score of 2.43 beat Aldeyra Therapeutics' score of 0.84 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Very Positive
Aldeyra Therapeutics	Positive

Summary

TherapeuticsMD and Aldeyra Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to PolyPid?

PolyPid (NASDAQ:PYPD) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

In the previous week, PolyPid had 17 more articles in the media than TherapeuticsMD. MarketBeat recorded 19 mentions for PolyPid and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 2.43 beat PolyPid's score of 0.18 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Neutral
TherapeuticsMD	Very Positive

26.5% of PolyPid shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PolyPid has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

PolyPid presently has a consensus target price of $11.33, suggesting a potential upside of 139.10%. Given PolyPid's stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats PolyPid on 8 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 191.75%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of -6.64% compared to Verrica Pharmaceuticals' net margin of -102.84%. TherapeuticsMD's return on equity of -1.09% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TherapeuticsMD has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.40	-$17.89M	-$1.67	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 2 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 2.43 beat Verrica Pharmaceuticals' score of 1.08 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Positive
TherapeuticsMD	Very Positive

Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Summary

Verrica Pharmaceuticals and TherapeuticsMD tied by winning 8 of the 16 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.96M	$11.80B	$7.03B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.64%
P/E Ratio	34.50	779.99	271.26	25.40
Price / Sales	7.93	748.58	622.95	105.59
Price / Cash	44.37	89.04	75.70	53.27
Price / Book	0.88	11.60	12.92	6.21
Net Income	-$570K	$2.77B	$3.45B	$347.71M
7 Day Performance	N/A	0.14%	1.16%	1.08%
1 Month Performance	1.47%	0.65%	2.17%	1.87%
1 Year Performance	76.94%	145.68%	62.38%	20.79%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	1.9507 of 5 stars	$2.07 -0.5%	N/A	+76.9%	$23.96M	$3.02M	34.50	420	Positive News Earnings Report Analyst Upgrade
RFAI RF Acquisition Corp II	1.9028 of 5 stars	$11.09 -0.3%	N/A	+4.5%	$92.78M	N/A	N/A	N/A	News Coverage Positive News Earnings Report Short Interest Decrease
FBIO Fortress Biotech	2.3682 of 5 stars	$2.61 -5.1%	$17.00 +551.3%	+38.2%	$91.35M	$63.26M	0.82	170	News Coverage Earnings Report Analyst Downgrade Gap Down
ALDX Aldeyra Therapeutics	3.2496 of 5 stars	$1.51 flat	$5.50 +264.2%	-71.1%	$91.09M	N/A	N/A	10	News Coverage Analyst Downgrade
PYPD PolyPid	3.0177 of 5 stars	$4.73 -0.8%	$11.33 +139.6%	+37.4%	$91.03M	N/A	N/A	80	News Coverage Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. RFAI, FBIO, ALDX, PYPD, and VRCA

How does TherapeuticsMD compare to RF Acquisition Corp II?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Summary

How does TherapeuticsMD compare to Aldeyra Therapeutics?

Summary

How does TherapeuticsMD compare to PolyPid?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. RFAI, FBIO, ALDX, PYPD, and VRCA

How does TherapeuticsMD compare to RF Acquisition Corp II?

Is RFAI or TXMD more profitable?

Which has higher earnings and valuation, RFAI or TXMD?

Do analysts prefer RFAI or TXMD?

Do institutionals & insiders believe in RFAI or TXMD?

Does the media refer more to RFAI or TXMD?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Which has more volatility and risk, FBIO or TXMD?

Is FBIO or TXMD more profitable?

Which has preferable valuation and earnings, FBIO or TXMD?

Do institutionals and insiders believe in FBIO or TXMD?

Do analysts prefer FBIO or TXMD?

Does the media refer more to FBIO or TXMD?

Summary

How does TherapeuticsMD compare to Aldeyra Therapeutics?

Which has higher valuation & earnings, TXMD or ALDX?

Do analysts prefer TXMD or ALDX?

Is TXMD or ALDX more profitable?

Do insiders and institutionals believe in TXMD or ALDX?

Which has more risk & volatility, TXMD or ALDX?

Does the media prefer TXMD or ALDX?

Summary

How does TherapeuticsMD compare to PolyPid?

Which has more risk & volatility, PYPD or TXMD?

Which has better earnings and valuation, PYPD or TXMD?

Does the media favor PYPD or TXMD?

Do insiders and institutionals hold more shares of PYPD or TXMD?

Is PYPD or TXMD more profitable?

Do analysts prefer PYPD or TXMD?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Do analysts prefer VRCA or TXMD?

Is VRCA or TXMD more profitable?

Do institutionals & insiders believe in VRCA or TXMD?

Which has higher earnings & valuation, VRCA or TXMD?

Does the media favor VRCA or TXMD?

Which has more volatility & risk, VRCA or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools